robust
reliabl
cell
cultur
system
serumderiv
hcv
hcvser
establish
yet
presenc
neutral
antibodi
tropism
infect
overcom
obstacl
employ
lipidmedi
protein
intracellular
deliveri
reagent
pidr
permit
intern
protein
cell
although
entri
hcvcc
enhanc
treatment
pidr
entri
hcvser
hepatoma
cell
line
immort
primari
hepatocyt
hc
significantli
enhanc
pidr
treatment
entri
hcvser
cell
presenc
pidr
resist
neutral
antibodi
suggest
pidr
capabl
intern
hcvser
receptorindepend
manner
interestingli
pidrmedi
entri
hcvser
hcvcc
enhanc
addit
sera
chronic
hepat
c
patient
healthi
donor
addit
neutral
hcvcc
infect
antibodi
cancel
treatment
pidr
conclus
pidr
valuabl
tool
get
obstacl
neutral
antibodi
intern
hcv
cell
might
use
establish
vitro
propag
hcvser
million
individu
worldwid
infect
hepat
c
viru
hcv
hepat
steatosi
cirrhosi
hepatocellular
carcinoma
hcc
induc
hcv
infect
lifethreaten
although
combinedtherapi
peginterferon
ifn
ribavirin
achiev
sustain
virolog
respons
individu
infect
hcv
genotyp
effect
therapeut
modal
hcv
infect
need
end
detail
analys
hcv
need
order
clarifi
viral
life
cycl
also
pathogenesi
although
cell
cultur
system
hcv
hcvcc
establish
base
strain
isol
fulmin
hepat
c
patient
system
unabl
establish
chronic
infect
chimpanze
induc
cell
damag
inflamm
chimer
mice
xenotranspl
human
hepatocyt
therefor
establish
robust
cell
cultur
system
capabl
propag
serumderiv
hcv
hcvser
hepat
c
patient
requir
although
previou
report
suggest
partial
replic
hcvser
primari
hepatocyt
phh
freshli
isol
human
liver
level
viral
rna
replic
low
reconfirm
viral
propag
achiev
due
difficulti
provid
stabl
suppli
phh
recent
shown
threedimension
cultur
system
immort
phh
capabl
propag
hcvser
chronic
hepat
c
patient
hcvser
patient
slightli
amplifi
cultur
system
level
viral
rna
replic
far
lower
hcvcc
adapt
cell
line
part
difficulti
establish
cell
cultur
system
hcvser
might
attribut
exist
high
titer
neutral
antibodi
sera
hepat
c
patient
ii
heterogen
hcv
particl
quasispeci
exhibit
differ
cell
tropism
infect
replic
iii
inconsist
express
put
receptor
hcv
entri
includ
srbi
occludin
may
necessari
overcom
obstacl
robust
reliabl
vitro
cell
cultur
system
establish
hcvser
polybren
use
effici
infect
retroviru
spinocul
also
employ
acceler
entri
variou
virus
includ
retroviru
murin
coronaviru
entri
hcvcc
permiss
cell
line
also
nonpermiss
cell
line
shown
enhanc
spinocul
studi
examin
effect
acceler
procedur
entri
hcvser
found
cation
amphiphilicbas
lipidmedi
protein
intracellular
deliveri
reagent
pidr
exhibit
potent
enhanc
entri
hcvser
data
suggest
pidr
allow
complex
format
viral
particl
via
electrostat
hydrophob
interact
enhanc
intern
hcvser
cell
receptorindepend
manner
sera
chronic
hepat
c
patient
cure
patient
possess
antihcv
antibodi
obtain
kyushu
univers
hospit
obtain
full
inform
consent
patient
seven
serum
sampl
hepat
c
patient
includ
two
windowperiod
serum
sampl
without
detect
antihcv
antibodi
obtain
benesi
corpor
osaka
japan
human
sera
healthi
donor
obtain
sigmaealdrich
inc
st
loui
mo
sera
healthi
donor
chronic
hepat
patient
acut
hepat
patient
design
hd
ch
ah
respect
hcvrna
titer
ch
ah
ae
rang
ae
rang
respect
genotyp
hcv
sera
patient
patient
cell
line
obtain
american
type
cultur
collect
rockvil
md
cell
line
exhibit
effici
propag
hcvcc
describ
previous
cell
line
stabli
express
human
establish
describ
previous
kindli
provid
hijikata
kyoto
univers
hc
immort
human
liver
cell
line
purchas
appli
cell
biolog
research
institut
kirkland
wa
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
sigma
contain
fetal
bovin
serum
fb
vitro
transcrib
rna
strain
hcv
introduc
cell
cultur
supernat
collect
day
posttransfect
use
hcvcc
infect
hcvcc
determin
focu
form
assay
previous
describ
plasmid
transfect
cell
liposomemedi
transfect
use
miru
madison
wi
protein
introduc
cell
pidr
pulsin
polyplustransfect
inc
new
york
ny
accord
manufactur
protocol
fitcconjug
mous
igg
antibodi
invitrogen
molecular
probe
eugen
recombin
phycoerythrin
pe
polyplustransfect
inc
introduc
cell
pidr
posit
control
total
rna
prepar
cell
use
rneasi
mini
kit
qiagen
tokyo
japan
synthesi
firststrand
cdna
qrtpcr
perform
use
taqman
ez
rtpcr
core
reagent
abi
prism
system
appli
biosystem
japan
tokyo
japan
accord
manufactur
protocol
primer
taqman
pcr
design
noncod
region
previous
report
cell
seed
cellswel
plate
cultur
h
spinocul
ml
hcvposit
serum
hcvcc
multipl
infect
moi
inocul
cell
immedi
centrifug
g
min
room
temperatur
infect
hcv
polybren
pidr
mg
polybren
ml
pidr
incub
hcvposit
serum
hcvcc
dilut
ml
phosphatebuff
salin
pb
min
room
temperatur
allow
complex
format
cell
trypsin
h
postinocul
seed
plate
remov
nonspecif
bind
hcv
cultur
sever
day
pseudotyp
vsv
gener
describ
previous
pseudotyp
vsv
vsvpvgfp
vsvpvluc
bore
vsvg
protein
virion
surfac
replac
g
envelop
gene
green
fluoresc
protein
gfp
luciferas
gene
respect
pseudotyp
vsv
bear
hcv
glycoprotein
hcvpv
prepar
describ
previous
pseudotyp
virus
inocul
cell
presenc
absenc
pidr
togeth
without
antivsvg
polyclon
antibodi
abcam
inc
cambridg
ch
infect
determin
h
postinfect
express
gfp
luciferas
activ
treatment
passiv
lysi
buffer
promega
co
madison
wi
determin
involv
human
intracellular
deliveri
hcv
pidr
cell
pretreat
mgml
antihuman
monoclon
antibodi
bd
bioscienc
pharmingen
mountain
view
ca
h
c
inocul
hcvcc
hcvser
presenc
pidr
monoclon
antibodi
kindli
provid
ah
patel
univers
glasgow
premix
hcvcc
h
without
pidr
cell
incub
mixtur
cultur
sever
day
first
examin
effect
spinocul
entri
hcvser
hcvcc
intracellular
hcvrna
titer
cell
upon
infect
hcvser
hcvcc
without
spinocul
h
postinfect
determin
data
shown
although
entri
hcvcc
cell
increas
spinocul
effect
observ
entri
hcvser
next
examin
effect
polybren
entri
hcvser
hcvcc
cell
although
polybren
induc
slight
increas
entri
hcvcc
signific
effect
entri
hcvser
observ
intracellularli
h
postinfect
data
shown
result
indic
neither
spinocul
polybren
induc
enhanc
entri
hcvser
determin
efficaci
intracellular
deliveri
protein
pidr
fitcconjug
mous
igg
recombin
pe
introduc
cell
pidr
fitcconjug
igg
pe
effici
intern
cell
treatment
pidr
lipofect
fig
next
determin
receptorindepend
entri
viral
particl
cell
pidr
express
gfp
upon
infect
pseudotyp
vsv
lack
vsvg
cell
examin
although
lost
infect
due
lack
g
glycoprotein
addit
pidr
facilit
entri
particl
fig
examin
effect
presenc
neutral
antibodi
deliveri
viral
particl
pidr
express
gfp
upon
transduct
vsvpvgfp
cell
presenc
neutral
antibodi
pidr
examin
although
vsvpvgfp
exhibit
high
infect
cell
infect
complet
neutral
antivsvg
antibodi
treatment
pidr
partial
recov
infect
vsvpvgfp
neutral
antibodi
fig
similar
result
confirm
use
vsvpvluc
carri
luciferas
gene
report
fig
result
indic
pidr
use
tool
facilit
entri
viral
particl
target
cell
irrespect
authent
envelop
protein
particl
presenc
neutral
antibodi
determin
effect
pidr
infect
hcv
hcvcc
inocul
cell
moi
presenc
absenc
pidr
intracellular
viral
rna
measur
everi
h
signific
differ
infect
hcvcc
observ
addit
pidr
fig
next
mimic
infect
hcv
presenc
neutral
antibodi
hcvcc
mix
ch
inocul
cell
although
infect
hcvcc
complet
neutral
incub
ch
addit
pidr
recov
infect
hcvcc
fig
furthermor
confirm
effect
pidr
intern
hcvcc
interact
neutral
antibodi
hcvcc
preincub
inocul
cell
although
infect
hcvcc
neutral
treatment
dosedepend
manner
neutral
cancel
treatment
pidr
fig
result
suggest
pidr
abil
intern
hcvcc
even
presenc
neutral
antibodi
effici
neutral
activ
hcv
infect
ch
comfirm
neutral
assay
use
pseudotyp
virus
infect
hcvpv
bear
hcv
protein
vsvpv
bear
vsvg
protein
significantli
neutral
ch
fig
next
determin
effect
pidr
entri
hcvser
presenc
neutral
antibodi
hcvser
ch
possess
neutral
antibodi
hcv
inocul
cell
without
incub
pidr
cell
inocul
ch
preincub
pidr
exhibit
significantli
higher
hcvrna
titer
h
postinfect
without
treatment
fig
furthermor
determin
amount
hcv
intern
cell
cell
inocul
ch
treat
pidr
trypsin
reseed
new
cultur
plate
h
postinfect
hcvrna
detect
cell
inocul
ch
preincub
pidr
without
pidr
treatment
h
reseed
fig
result
indic
treatment
pidr
permit
hcvser
intern
target
cell
even
presenc
neutral
antibodi
reduct
infect
hcvpv
vsvpv
observ
incub
ah
suggest
ah
possess
detect
neutral
antibodi
hcv
fig
examin
effect
neutral
antibodi
intracellular
deliveri
hcvser
pidr
ah
incub
ch
carri
neutral
antibodi
infecti
hcv
obtain
patient
cure
interferon
therapi
presenc
absenc
pidr
inocul
cell
intern
hcv
ah
increas
twofold
treatment
pidr
howev
intracellular
viral
rna
titer
slightli
decreas
incub
ch
absenc
pidr
probabl
due
neutral
antibodi
addit
pidr
result
threefold
enhanc
entri
hcv
ah
presenc
ch
compar
absenc
ch
fig
next
cell
inocul
hcvcc
moi
incub
mlml
hcvneg
ch
presenc
absenc
pidr
although
infect
hcvcc
neutral
ch
dosedepend
manner
addit
pidr
enhanc
infect
hcvcc
presenc
ch
dosedepend
manner
fig
result
indic
pidr
facilit
entri
hcvser
presenc
neutral
antibodi
next
determin
involv
human
major
receptor
candid
hcv
pidrmedi
entri
hcvser
cell
pretreat
antibodi
inocul
hcvser
treat
pidr
although
pretreat
antibodi
result
signific
reduct
entri
hcvser
treatment
pidr
enhanc
entri
hcvser
irrespect
presenc
antihuman
fig
addit
although
entri
hcvser
cell
low
independ
express
treatment
pidr
enhanc
entri
hcvser
irrespect
express
human
fig
result
suggest
pidrmedi
entri
hcvser
independ
express
effect
entri
hcvser
variou
cell
line
cell
line
recent
ali
et
al
report
immort
human
hepatocyt
cell
exhibit
high
suscept
infect
hcvser
therefor
examin
effect
pidr
entri
hcvser
immort
human
hepatocyt
includ
hc
cell
addit
pidr
enhanc
entri
hcvser
hc
cell
fig
b
result
indic
pidr
potenti
enhanc
entri
hcvser
cancer
cell
line
also
immort
hepatocyt
next
evalu
longterm
effect
pidr
treatment
infect
hcvser
hc
cell
inocul
ch
preincub
pidr
cultur
long
period
hcvrna
could
detect
day
pidrmedi
infect
fig
howev
signific
elev
hcvrna
titer
seen
data
shown
studi
examin
effici
intracellular
deliveri
hcvser
use
spinocul
polybren
pidr
found
pidr
exhibit
highest
efficaci
entri
hcvser
target
cell
especi
trypsin
reseed
cell
dramat
reduc
hcvrna
level
group
treat
pidr
compar
treat
pidr
fig
c
pidr
treatment
dramat
increas
intern
hcvcc
treat
ch
day
infect
fig
c
result
suggest
pidr
feasibl
deliv
hcvch
complex
target
cell
allow
product
infect
addit
pidr
facilit
entri
hcvser
hepatoma
cell
line
immort
human
hepatocyt
manner
furthermor
demonstr
intracellular
deliveri
hcvser
pidr
enhanc
addit
antihcv
antibodi
sera
chronic
hepat
c
patient
suggest
pidr
effect
reagent
intracellular
deliveri
hcvser
target
cell
receptorindepend
manner
although
direct
evid
enhanc
adsorpt
penetr
applic
spinocul
polybren
demonstr
yet
sediment
viru
particl
cell
surfac
spinocul
electrostat
interact
viral
particl
cell
charg
polybren
suggest
overcom
first
barrier
viru
particl
cell
pidr
cation
amphiphilicbas
protein
deliveri
reagent
form
complex
protein
electrostat
hydrophob
interact
complex
protein
molecul
pidr
shown
interact
heparan
sulfat
proteoglycan
cell
surfac
intern
endocytosi
protein
molecul
releas
complex
cytoplasm
suggest
pidr
capabl
enhanc
adsorpt
also
penetr
hcvser
although
hcvser
compos
heterogen
viral
popul
larg
fraction
viral
particl
associ
lipoprotein
neutral
antibodi
particl
capabl
invad
human
hepatocyt
establish
persist
infect
vivo
therefor
feasibl
specul
host
factor
involv
entri
hcvser
hepatocyt
vivo
recent
stamataki
et
al
suggest
peripher
blood
b
lymphocyt
particip
reservoir
hcv
persist
infect
vehicl
transinfect
hepatocyt
although
precis
mechan
entri
hcv
clarifi
yet
pidr
effici
modal
overcom
obstacl
entri
hcv
recent
studi
reveal
least
four
cellular
molecul
play
crucial
role
infect
hcv
hepatocyt
vitro
scaveng
receptor
class
b
type
srbi
tight
junction
protein
occludin
studi
entri
hcvser
treatment
pidr
shown
independ
although
involv
receptor
candid
examin
studi
pidr
shown
enhanc
entri
hcvser
cell
line
includ
hc
suggest
pidr
capabl
enhanc
entri
hcv
pathway
independ
express
receptor
candid
previou
studi
indic
hcv
infect
hepatocyt
also
lymphoid
tissu
peripher
blood
mononuclear
cell
quasispeci
natur
viral
particl
differ
among
tissu
infect
hcv
furthermor
shown
vitro
transcrib
rna
use
recoveri
infecti
particl
contain
copiesmg
much
higher
amount
viral
rna
detect
patient
sera
varieti
cell
tropism
depend
quasispeci
hcv
particl
low
viral
load
sera
coexist
neutral
antibodi
lack
identifi
cofactor
includ
function
environ
liver
might
major
obstacl
establish
cell
cultur
system
propag
hcvser
sever
approach
taken
establish
vitro
cell
cultur
system
hcv
includ
cultur
human
liver
cell
threedimension
radialflow
bioreactor
threedimension
cultur
immort
primari
hepatocyt
micropattern
cultur
primari
hepatocyt
innov
approach
cell
cultur
liver
cell
combin
pidr
abl
overcom
first
barrier
hcv
propag
might
contribut
breakthrough
establish
robust
cell
cultur
system
hcvser
studi
demonstr
pidr
abl
intern
hcv
receptorindepend
manner
provid
clue
toward
develop
cell
cultur
system
hcvser
presenc
neutral
antibodi
pidr
may
also
use
studi
virus
difficult
intern
cell
due
low
viral
titer
presenc
neutral
antibodi
